St. Jude Children's Research Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, St. Jude Children's Research Hospital sits in the top decile of US sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count).
St. Jude Children's Research Hospital: 410 sponsored US clinical trials, 90 recruiting.
St. Jude Children's Research Hospital sponsors 410 registered US clinical trials on ClinicalTrials.gov, 90 of them currently recruiting, and 227 completed. 19 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 17 trials.
Top-decile sponsor footprint
St. Jude Children's Research Hospital ranks in the top decile of sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
227 of 259 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
410 total, page 1 of 9
Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Survivors
NCT07516301
Bereaved Parent Conversations on Hope
NCT07675083
Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients
NCT07502885
Outcomes of Health Care Transition for AYA With a Cancer Predisposition
NCT07456904
Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
NCT07222345
Functional Ovarian Reserve in Sickle Cell Disease
NCT07392216
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
NCT07428993
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
NCT07228741
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
NCT06528691
Stakeholders of Rare Diseases Informing Values In Neuroethics
NCT07314736
A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer
NCT07444216
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
NCT07257419
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
NCT07191119
Evaluation Of Cardiovascular Health Outcomes Among Survivors 2
NCT07245420
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
NCT07085325
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
NCT07222735
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
NCT06579469
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
NCT07226219
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
NCT07085338
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
NCT06532474
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
NCT07048535
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
NCT07052370
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
NCT07110519
Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer: A Randomized Clinical Trial
NCT07160621
Seminar in Unwavering Empowering Presence Optimized for Rehabilitation Teams
NCT07071116
Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).
NCT05664113
Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
NCT06646640
Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit
NCT06993688
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
NCT06819475
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
NCT06810583
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
NCT06847269
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
NCT06777979
School Readiness Intervention for Preschool Children With Sickle Cell Disease
NCT06367192
Gene Editing For Sickle Cell Disease
NCT06506461
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
NCT06747910
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
NCT06533748
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06390319
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06289673
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
NCT06442761
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
NCT06480526
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463
Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease
NCT06477289
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
NCT06421987
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
NCT06098430
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06239272
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
NCT06023641
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
NCT04881240
Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition
NCT05849155
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
NCT05645523
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 86 |
| Phase 3 | 17 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the St. Jude Children's Research Hospital pipeline
90 recruiting of 410 indexed (22% open); 227 completed (55%).
Phase mix: 19 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Sickle Cell Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
St. Jude Children's Research Hospital: open-pipeline peers nationwide
Peers matched on 410 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
St. Jude Children's Research Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 410 trials (± recruiting share)
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Rutgers, The State University of New Jersey · 413 trials · 26% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Northwell Health · 22% recruiting · 370 trials
- Vanda Pharmaceuticals · 22% recruiting · 68 trials
- Boston University Charles River Campus · 22% recruiting · 104 trials
- Regeneron Pharmaceuticals · 22% recruiting · 280 trials
Related
What to do with this St. Jude Children's Research Hospital page
410 registered trials is a research-attention snapshot, not an endorsement of St. Jude Children's Research Hospital or any single study.
- 90 of St. Jude Children's Research Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sickle Cell Disease is the condition St. Jude Children's Research Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
St. Jude Children's Research Hospital pipeline card: 410 registered trials from official public datasets.Report a data error.